Arcturus wins bullish call on vaccine potential, Novocure downgraded – in today’s analyst action

Mario13/E+ via Getty Images
Arcturus wins new bullish call at Cantor on experimental COVID-19 shot

  • Arcturus Therapeutics (NASDAQ:ARCT) has added ~1.3%
     in the pre-market after Cantor Fitzgerald initiated its coverage with an overweight recommendation highlighting…

Click here to view the original article.